Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments

The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority receiving the due their diminished immunity. This study reports response rate of administering third fourth doses cancer active anti-neoplastic treatment. A total 142 received two mRNA-based COVID-19 vaccine, while 76 25 three four doses, respectively. efficacy humoral following was in patients, especially group chemotherapy. In a multivariate analysis, who were more likely antibody titers upper tertile compared (odds ratio (OR) 7.62 (95% CI 1.38–42.12), p = 0.02 17.15 5.01–58.7), < 0.01, respectively). Unlike after booster an increased 95–100% undergoing result could be explained by different mechanisms including development memory B cells.